An investigator presented extended follow-up data from a phase 3 trial on aglatimagene besadenovec (CAN-2409) + prodrug in combination with standard-of-care EBRT in men with localized prostate cancer.

EBRT with or without STAD showed similar 15-year PCSS and OS rates in IRPC patients, with high PSA failure rates observed. Multivariate analysis indicated greater side effects in the STAD group ...

Results from the NRG Oncology NRG-RTOG 0232 clinical trial adding external beam radiotherapy (EBRT) to brachytherapy (BT) in men with intermediate-risk prostate cancer indicate that there was no ...

Adjuvant EBRT after RP may prolong biochemical PFS and MFS but not OS in patients with positive surgical margins, extracapsular extension, or seminal vesicle invasion, supporting a shared ...

Adding supplemental external beam radiotherapy (EBRT) did not improve outcomes in higher-risk cancer patients who had brachytherapy, according to the long-term results of two trials. Specifically, ...

NRG-RTOG 0232 randomly assigned588 men with intermediate-risk prostate cancer to either the COMBO or the BT treatment arm and 579 were eligible/analyzed. The COMBO arm consisted of 287 patients versus ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...

Breaking News of Cancer Diagnosis: A Qualitative Study on the Experiences and Emotional Needs of Patients With Cancer in a Multiethnic Asian Setting Updates to consensus guidelines in October 2018 ...

Reviewed by Peter E. Lonergan, MD, FRCS (Urol.), consultant urologist and clinical senior lecturer at St. James’s Hospital & Trinity College in Dublin, Ireland. If you have prostate cancer and ...